Alnylam Launches Digital Tool for ATTR Amyloidosis Patients in UK

The Alnylam has been a pioneer in the hereditary ATTR amyloidosis, along with getting the approval in the year 2018 for the first drug for the purpose of treating the rare disease, and it has also launched a digital companion for the purpose of helping the patients for tracking their symptoms.

The new app of the company, that is called as STAR, has been responsible for allowing the patients to record their symptoms along with sharing them with the healthcare professionals for the purpose of encouraging what the company said is more impactful and confident discussions.

The hereditary ATTR amyloidosis has been an aggressive and rapidly progressing, along with debilitating and the fatal disease, and this launch of the Onpattro of Alnylam had been a milestone for the patients and also for the biopharma industry, and it had been the first drug for being approved in the United States, that has been working by the interference of RNA that has been transcribing a defective gene in the DNA of a patient into a misfolded protein that is responsible in leading it to a disease.

Dr. Dinesh Kumar, medical director of Alnylam for Ireland and UK said, the STAR had been designed for the purpose of helping the patients for better understanding their condition along with its impact on the quality of life, that is also including their ability for continuing the day-to-day activities, along with the energy levels, mood and relationships with the friends and family.